Journal
ACTAS DERMO-SIFILIOGRAFICAS
Volume 103, Issue 7, Pages 579-590Publisher
ELSEVIER ESPANA
DOI: 10.1016/j.ad.2011.08.009
Keywords
Melanoma; Therapeutic targets; Molecular targets; BRAF; C-kit; Anti CTLA-4
Categories
Ask authors/readers for more resources
Research into molecular targets for drug development in melanoma is starting to bear fruit. Of the drugs tested to date in patients with metastatic melanoma, those that have yielded the best results are V600E BRAF inhibitors in melanomas carrying the V600E mutation; c-kit tyrosine kinase activity inhibitors in melanomas carrying c-kit mutations; and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies, which block the mechanisms involved in immune tolerance. Many problems have yet to be resolved in these areas, however, such as the rapid development of resistance to BRAF and c-kit inhibitors and the lack of biomarkers to predict treatment response in the case of CTLA-4 blockers. We review the results of targeted therapy with these and other drugs in metastatic melanoma and discuss what the future holds for this field. (C) 2011 Elsevier Espana, S.L. and AEDV. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available